Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.31 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1194394 | 0.81 | ALDH1A1 (0.42) | GSK3BPTPN1HPGDS | |
| SCHEMBL1194761 | 0.81 | PTPN1 (0.34) | GSK3BPTPN1HPGDSPTGS2PTGS1 | |
| SCHEMBL1194802 | 0.79 | HSD17B1 (0.34) | PTGS2WDR5PTGS1AKR1C3AKR1C2 | |
| SCHEMBL30195364 | 0.77 | PTPN1 (0.52) | GSK3BPTPN1HPGDS | |
| SCHEMBL615669 | 0.77 | PTPN1 (0.52) | GSK3BPTPN1HPGDS | |
| SCHEMBL4000497 | 0.76 | GSK3B (0.52) | GSK3BPTPN1HPGDS | |
| SCHEMBL28799656 | 0.74 | PTPN1 (0.50) | GSK3BPTPN1HPGDS | |
| SCHEMBL30702134 | 0.73 | GSK3B (0.52) | GSK3BPTPN1 | |
| SCHEMBL5055150 | 0.73 | GSK3B (0.52) | GSK3BPTPN1HPGDS | |
| SCHEMBL7779200 | 0.73 | GSK3B (0.52) | GSK3BPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| US-8466169-B2 | SF5 derivatives as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2013-06-18 | — | — | US | disclosed |
| EP-2242740-B1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-12-12 | — | — | EP | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
| WO-2009097972-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034461-A1 | SF5 DERIVATIVES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL1, F2RL3 | GSK3B 2612/4885PTPN1 1291/4885HPGDS 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.